

**For immediate release: Tuesday 5 February 2013**

## **European research consortium initiates clinical trial using innovative eye drop treatment to combat diabetic retinopathy**

A clinical trial to evaluate a new therapeutic treatment using eye drops for the early stages of diabetic retinopathy started this week, researchers announced. A group of leading European ophthalmologists, endocrinologists and researchers have gathered together with BCN Peptides (a biopharmaceutical SME) under EUROCONDOR, the European Consortium on the early treatment of diabetic retinopathy, and will conduct the clinical trial in 11 clinical centres across the EU.

Diabetic retinopathy is an eye disease that occurs in people living with diabetes. It involves changes in the tiny blood vessels that nourish the retina at the back of the eye which can ultimately lead to severe loss of vision or even blindness. Today, diabetic retinopathy is the leading cause of preventable blindness among working-age individuals in developed countries.

Along with the human suffering from this devastating complication comes an increasingly heavy economic burden: healthcare costs for patients with diabetic retinopathy are almost double that of patients without the complication.

There is growing evidence to suggest that retinal neurodegeneration plays an important role in the onset of diabetic retinopathy. With this in mind, EUROCONDOR will conduct a controlled phase II and III clinical trial to assess whether therapeutic strategies based on neuroprotection are effective not only in preventing or arresting retinal neurodegeneration but also in preventing the development and progression of the early stages of diabetic retinopathy.

The trial will evaluate the safety and effectiveness of a new therapeutic eye drop treatment based on two neuroprotective drugs: somatostatin (a peptide hormone) and brimonidine (a drug currently used to treat glaucoma).

“Until recently, the use of eye drops has not been considered an appropriate route for the administration of drugs in the early treatment of this complication because of the general assumption that they do not reach the retina”, comments Dr Rafael Simó, Director of Diabetes Research and Metabolism Unit at VHIR (Hospital Universitari de la Vall d’Hebrón – Institut de Recerca) and coordinator of the EUROCONDOR project. “However, recent studies show that many drugs are able to reach the retina in effective concentrations.”

These findings mean that neuroprotective drugs administered through eye drops have the potential to open up a new strategy to treat the early stages of diabetic retinopathy. Positive outcomes for the EUROCONDOR project could have a considerable impact on prevention, placing neurodegeneration as a new target for early detection of diabetic retinopathy in people with diabetes.

IDF Europe is a partner of EUROCONDOR. The role of the Federation will be to disseminate the findings of the research to the diabetes community in Europe.

The EUROCONDOR project is an important step in the development of a new, non-invasive treatment for this devastating complication of diabetes, given early in the disease. It is hoped that the findings of this research will help pave the way for new screening systems that will allow to diagnose diabetic retinopathy at earlier stages, which in turn would allow to provide better care for patients.

The EUROCONDOR project, which is funded by the 7th Framework Programme (FP7) of the European Union, began in March 2012 and is scheduled to be completed in February 2016.

-----

### Notes to editors:

EUROCONDOR is a collaborative project funded by the European Commission under the 7th Framework Programme. The project is coordinated by the Fundació Hospital Universitari Vall d'Hebrón - Institut de Recerca (VHIR). The EUROCONDOR consortium includes 17 partners across Europe, of which 11 clinical centres that will recruit patients to carry out the trial.

For the full list of project partners, go to [www.eurocondor.eu/partners](http://www.eurocondor.eu/partners)

For more information about EUROCONDOR, visit [www.eurocondor.eu](http://www.eurocondor.eu)

For more information on the EU's 7<sup>th</sup> Framework Programme, go to <http://cordis.europa.eu/fp7>

Please note that the present press release reflects only the author's views and the European Union is not liable for any use that may be made of the information contained therein.

### Press contact

*On behalf of the EUROCONDOR consortium:*

**Gaël Bassetto**, Communication Officer  
International Diabetes Federation European Region – IDF Europe  
166, Chaussée de la Hulpe, 1170 Brussels (Belgium)  
T: +32 (0)2 639 20 91  
M: +32 (0)490 39 89 99  
E: [gael.bassetto@idf-europe.org](mailto:gael.bassetto@idf-europe.org)

*VHIR Communication Officer*

**Fran Garcia**, Communication Officer  
M: +34 666215168  
E: [fran.garcia@vhir.org](mailto:fran.garcia@vhir.org)

*BCN Peptides Communication Officer*

**Lluís Riera**, Product Manager  
T: +34 938191399  
E: [lriera@bcnpeptides.com](mailto:lriera@bcnpeptides.com)